Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology, Pancreatitis, and Protease-Inhibitor Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for PRSS2 (Mesotrypsin / Trypsin-2) drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen / Enzyme | PRSS2 Recombinant Protein (Active and Zymogen forms, including catalytic-dead mutants S195A/S207A). High purity (>95%), Endotoxin <1EU/µg. Sequence Verified. HEK293 Expressed (Native Glycosylation). | View PRSS2 Products |
| Mutant Panel | PRSS2 Catalytic Dead Mutant (S195A / S207A) and selectivity variants. Theoretical MW confirmed. For binding vs activity studies. | View PRSS2 Products |
| Gene Delivery | PRSS2 Promise-ORF / Lentivirus. Full-length ORF for stable cell lines and secreted expression. | View PRSS2 Products |
| Benchmark / Detection Ab | Anti-PRSS2 Recombinant Monoclonal Antibody. Sequence Verified. For Western, ELISA, and functional blockade. | View PRSS2 Products |
| Validator | PRSS2 siRNA Set. For knockdown verification and specificity controls. | View PRSS2 Products |
| Related Target A | PRSS1 (Trypsin-1). Critical homology counter-target for selectivity screening. | View PRSS1 Products |
| Related Target B | SPINK1. Endogenous protease inhibitor; key interaction partner in tumor microenvironments and pancreatitis. | View SPINK1 Products |
| Related Target C | CTRC (Chymotrypsin C). Regulates trypsinogen activation and degradation pathway node. | View CTRC Products |
Critical Assay Challenges & The TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Trypsin Homolog Selectivity (PRSS1 vs PRSS2 vs PRSS3) | Strictly verified Sequence and Theoretical MW via mass spectrometry. High-purity homolog panel available for counter-screening. |
| Auto-degradation and Zymogen vs Active Conformation | Produced in mammalian systems (HEK293) for optimal folding and stability. Native Trypsinogen-2 (proenzyme) and auto-processed Active PRSS2 available. |
| Lack of Reliable Controls and False Positives | Catalytic-dead mutants (S195A, S207A) included as negative controls. Validated siRNA and Benchmark Antibodies for precise detection limits in phenotypic assays. |
| Cross-species Preclinical Evaluation | Ortholog proteins (Human/Mouse/Cyno) available with >95% purity and Sequence Verified for species-specific epitope mapping. |
| Enzymatic Activity Standardization | Active enzyme with defined specific activity units. Endotoxin controlled (<1 EU/µg) to prevent macrophage activation artifacts. |
Live PRSS2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for PRSS2 (Mesotrypsin/Trypsin-2) therapeutics is intensifying, with major players shifting focus from traditional broad-spectrum protease inhibitors to highly selective small molecules, neutralizing monoclonal antibodies, and innovative biologics. PRSS2 is increasingly implicated in tumor metastasis (particularly pancreatic and prostate cancers), refractory pancreatitis, and cystic fibrosis-associated pancreatic damage. First-generation therapies aim to overcome PRSS2's unique resistance to endogenous biological inhibitors (e.g., SPINK1) and achieve high selectivity over PRSS1 and PRSS3 to avoid off-target digestive side effects. The next wave of R&D is targeting allosteric modulation, zymogen-selective blockade, and tumor-microenvironment (TME) localized delivery. Combination approaches with CFTR modulators, chemotherapy, or immune checkpoint inhibitors are emerging. Key challenges include achieving >100-fold selectivity over PRSS1, developing stable inhibitors resistant to self-degradation, and validating target engagement in translational models.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitor | Preclinical Biotech, Academic Spin-offs, Academic Consortia | Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma (PDAC), Acute & Chronic Pancreatitis | Selectivity Assay (Need high-purity PRSS1/PRSS2/PRSS3 homolog panel and mutant variants) |
| Monoclonal Antibody | Top Tier Pharma, Specialty Oncology Cos | Prostate Cancer Metastasis, PRSS2+ Solid Tumors | Epitope Mapping & Neutralization (Need HEK293 expressed native fold proteins and catalytic-dead mutants for binding specificity) |
| siRNA / Gene Therapy | RNAi Focus Companies, Discovery-stage Programs | Refractory Inflammation, Chronic Pancreatitis | Knockdown Validation (Need sequence-verified antibodies and lentivirus for loss/gain-of-function studies) |
| Biologic / Peptide Mimetic (Serpins) | Protein Engineering Labs | Acute Pancreatitis, Cystic Fibrosis | SPR Binding Kinetics (Need high-purity active and zymogen PRSS2 for affinity ranking) |
| Antibody-Drug Conjugate (ADC) | Emerging Biotech | Solid Tumors (PRSS2+) | Internalization Assay (Need active enzyme uptake validation) |
Key Functional Domains & Mutations
PRSS2 (UniProt P07478) belongs to the Peptidase S1 family, characterized by the classical serine protease catalytic triad (His, Asp, Ser). Key known mutations include:
- dbSNP rs11547028: A coding variant that may affect protein function or stability (UniProt VAR_051858).
- dbSNP rs1804564: This mutation abolishes tyrosine sulfation, potentially altering post-translational modification and interaction with substrates/inhibitors (UniProt VAR_071761).
Understanding these natural variants is critical for designing selective inhibitors that accommodate polymorphic diversity.